Cardio3 Biosciences Announces New Business Development Strategy To Broaden Its Product Pipeline

MONT-SAINT-GUIBERT, Belgium, October 1, 2014 /PRNewswire/ --

• Cardio3 BioSciences' business development strategy will be articulated around a technology pillar - cellular therapies - and a clinical application pillar - cardiovascular diseases - to further strengthen its long term growth 
• This strategy aims to expand the Company's product portfolio and generate multiple short term value creation milestones 

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases.

Since its inception, Cardio3 BioSciences has demonstrated its competency in cellular therapy, from R&D to manufacturing, to regulatory clinical trials; Cardio3 BioSciences is now engaged in C-Cure®'s Phase III regulatory pivotal trials process in Europe, U.S., and China. Cardio3 BioSciences has developed in parallel its technical expertise in medical devices, with the manufacturing of a proprietary cell delivery system, C-Cath_ez®. Finally, the Company, with its deep understanding of cardiology, led to the close collaboration with a unique network of top-ranking cardiovascular institutions around the world. These accomplishments represent a solid platform for further growth.

This focussed approach to business development around a technology pillar (cellular therapies) and a clinical application pillar (cardiovascular diseases), will lead to a number of unmet medical needs and market opportunities across different therapeutic approaches in cellular therapies and cardiovascular diseases. In cellular therapies, this could cover applications in immune modulation, regeneration or oncology. In cardiovascular diseases this could lead to multiple treatment modalities, such as devices or biologics.

Cardio3 BioSciences' business development strategy is intended to build a coherent, sustainable and highly profitable business entity building on the solid C-Cure® foundations.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said:  "We intend to build a strong sustainable world leader in the areas identified in our business development strategy. C-Cure® is the foundation of those efforts. Our efforts to bring C-Cure® to this stage have brought tremendous opportunities to further develop our business and to build on our core competences in the cardiovascular field, cellular therapies and medical devices. We can therefore bring our expertise to develop innovative therapies to more patients."

About Cardio3 BioSciences 

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences aims to develop innovative approaches to offer the best therapeutic response to unmet medical needs.

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_ez®, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. 

For more information, please contact: 

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager, Tél: +32-10-39-41 00, [email protected]
http://www.c3bs.com

Citigate Dewe Rogerson

Chris Gardner, Tel: +44(0)207-638-9571, [email protected]

SOURCE Cardio3 BioSciences (C3BS)